These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 19191252)

  • 21. Paying for Drugs After the Medicare Part D Beneficiary Reaches the Catastrophic Limit: Lessons on Cost Sharing from Other US Policy Partnerships Between Government and Commercial Industry.
    Padula WV; Ballreich J; Anderson GF
    Appl Health Econ Health Policy; 2018 Dec; 16(6):753-763. PubMed ID: 30058011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medicare program; Medicare prescription drug benefit; interpretation. Final rule; interpretation.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2005 Mar; 70(53):13397-400. PubMed ID: 15786588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medicare Part D: simplifying the program and improving the value of information for beneficiaries.
    Hoadley J
    Issue Brief (Commonw Fund); 2008 May; 39():1-15. PubMed ID: 18536148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medicare program; modification to the weighting methodology used to calculate the low-income benchmark amount. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2008 Apr; 73(65):18176-82. PubMed ID: 18464346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How insurers' bargaining power affects drug prices in Medicare Part D.
    Natl Bur Econ Res Bull Aging Health; 2009; (4):1-2. PubMed ID: 20355274
    [No Abstract]   [Full Text] [Related]  

  • 26. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
    Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
    JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvements in Medicare Part D risk adjustment: beneficiary access and payment accuracy.
    Kautter J; Ingber M; Pope GC; Freeman S
    Med Care; 2012 Dec; 50(12):1102-8. PubMed ID: 22922436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.
    Polinski JM; Mohr PE; Johnson L
    Arthritis Rheum; 2009 Jun; 61(6):745-54. PubMed ID: 19479704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of statin adherence among beneficiaries in MA-PD plans versus PDPs.
    Jung K; McBean AM; Kim JA
    J Manag Care Pharm; 2012 Mar; 18(2):106-15. PubMed ID: 22380470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 2007 costs and coverage of antiretrovirals under Medicare Part D for people with HIV/AIDS living in North Carolina.
    Sengupta S
    N C Med J; 2008; 69(1):6-13. PubMed ID: 18429558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relief in Sight - Estimated Savings under Medicare Part D Redesign.
    Dusetzina SB
    N Engl J Med; 2021 Dec; 385(26):e93. PubMed ID: 34758246
    [No Abstract]   [Full Text] [Related]  

  • 32. Should healthy Medicare beneficiaries postpone enrollment in Medicare Part D?
    Atherly A; Dowd B
    Health Econ; 2009 Aug; 18(8):921-31. PubMed ID: 18972327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost variability of suggested generic treatment alternatives under the Medicare Part D benefit.
    Patel RA; Walberg MP; Tong E; Tan F; Rummel AE; Woelfel JA; Carr-Lopez SM; Galal SM
    J Manag Care Spec Pharm; 2014 Mar; 20(3):283-90. PubMed ID: 24564812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How Medicare could get better prices on prescription drugs.
    Outterson K; Kesselheim AS
    Health Aff (Millwood); 2009; 28(5):w832-41. PubMed ID: 19643778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Why using current medications to select a medicare Part D plan may lead to higher out-of-pocket payments.
    Domino ME; Stearns SC; Norton EC; Yeh WS
    Med Care Res Rev; 2008 Feb; 65(1):114-26. PubMed ID: 17942795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A first look at the new Medicare prescription drug plans.
    Frakt AB; Pizer SD
    Health Aff (Millwood); 2006; 25(4):W252-61. PubMed ID: 16720588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding the Medicare Part D prescription program: partnerships for beneficiaries and health care professionals.
    De Natale ML
    Policy Polit Nurs Pract; 2007 Aug; 8(3):170-81. PubMed ID: 18178923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
    Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
    Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lessons learned: who didn't enroll in Medicare drug coverage in 2006, and why?
    Davidoff AJ; Stuart B; Shaffer T; Shoemaker JS; Kim M; Zacker C
    Health Aff (Millwood); 2010 Jun; 29(6):1255-63. PubMed ID: 20466775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medicare program; Medicare Advantage and prescription drug benefit programs: negotiated pricing and remaining revisions; prescription drug benefit program: payments to sponsors of retiree prescription drug plans. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2012 Jan; 77(8):1877-83. PubMed ID: 22359793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.